Redefining Hypo- and Hyper-Responding Phenotypes of CFTR Mutants for Understanding and Therapy.

Abstract excerpt

Mutations in CFTR cause misfolding and decreased or absent ion-channel function, resulting in the disease Cystic Fibrosis. Fortunately, a triple-modulator combination therapy (Trikafta) has been FDA-approved for 178 mutations, including all patients who have F508del on one allele. That so many CFTR mutants respond well to modulators developed for a single mutation is due to the nature of the folding process of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzodioxoles
• Share to Cystic Fibrosis
• Share to Cystic Fibrosis Research Advances